Loading
Global Burden of Disease / Third-dose Vaccine / Hepatitis B Vaccines · Journal article
Human Vaccines & Immunotherapeutics · July 31, 2026
Reinforces what was already believed, rather than introducing something new.
This is a descriptive spatiotemporal analysis of global hepatitis B third-dose vaccine coverage from 1980 to 2023 using GBD 2023 estimates across 204 countries and territories. It documents a substantial rise in global coverage from near 0% in the 1980s to 81.82% in 2023, with persistent regional disparities, and quantifies an annual increase of 2.50% (95% CI: 2.41%–2.59%, p<0.0001) via linear mixed-effects regression.
Descriptive spatiotemporal analysis using Global Burden of Disease 2023 estimates. All 204 countries and territories with available GBD 2023 HepB3 vaccine coverage estimates; regional stratification included Europe, Oceania, sub-Saharan Africa, and South Asia.. Intervention: Hepatitis B third-dose (HepB3) vaccination. n = 204. Global; 204 countries and territories.
Global HepB3 coverage increased from near 0% in the 1980s to 81.82% in 2023 Annual increase in coverage of 2.50% (95% CI: 2.41%–2.59%, p<0.0001) by linear mixed-effects regression Regional disparities evident: Europe and Oceania showed higher coverage; sub-Saharan Africa and South Asia lagged
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians and public health professionals should note that global HepB3 coverage has risen substantially but remains uneven; disparities in low-income regions and sub-Saharan Africa highlight where targeted vaccination efforts and health system strengthening are most urgent to reach the 2030 universal coverage goal.
Large descriptive analysis of global vaccine coverage trends across 204 countries using established GBD methodology, confirming previous observations of uneven HepB3 uptake and geographic disparities with quantified trend estimates.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians and public health professionals should note that global HepB3 coverage has risen substantially but remains uneven; disparities in low-income regions and sub-Saharan Africa highlight where targeted vaccination efforts and health system strengthening are most urgent to reach the 2030 universal coverage goal.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
The Hepatitis B third dose (HepB3) vaccination is essential in preventing chronic infections, liver failure, and cancer. Despite progress, global coverage remains uneven, especially in low-income regions. This study analyzes the global and regional spatiotemporal trends in HepB3 vaccine coverage from 1980-2023 using the Global Burden of Disease (GBD) 2023 estimates. Data from GBD 2023, covering 204 countries and territories from 1980 to 2023, was analyzed to assess HepB3 vaccine coverage. Descriptive statistics summarized global and regional trends, and linear mixed-effects regression models evaluated the impact of time and region on coverage. The study also utilized choropleth maps to visualize global and regional coverage variations. Global coverage increased from near 0% in the 1980s to 81.82% in 2023. Regional disparities were evident, with Europe and Oceania showing higher coverage, while sub-Saharan Africa and South Asia lagged. Regression results indicated an annual increase in coverage of 2.50% (95% CI: 2.41%-2.59%, p <.0001). Albania had the highest global coverage at 98.2%, while Somalia had the lowest at 14%. Global HepB3 coverage has significantly improved, but geographic disparities persist. Targeted interventions in low-coverage areas and strengthened healthcare systems are needed to meet the 2030 universal coverage goal.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.